Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiology
Bradykinin and metabolite bradykinin 1-5 inhibit thrombin-induced platelet aggregation
October 25th, 2006
Bradykinin and its metabolite bradykinin 1-5 inhibit thrombin-induced platelet aggregation in humans. According to a report from the United States, "Bradykinin 1-5 is a major stable metabolite of bradykinin, formed by the proteolytic action of angiotensin-converting enzyme. In vitro and animal studies suggest that bradykinin 1-5 possesses biological activity. This study tests the hypothesis that bradykinin 1-5 affects vasodilation, fibrinolysis, or platelet aggregation in humans." L.J. Murphey and colleagues at Vanderbilt University explained, "Graded doses of bradykinin (47 -377 pmol/min) and bradykinin 1-5 (47 -18,850 pmol/min) were infused in the...
Source: Biotech Week (2006-10-25)
|
